AOTI’s At-Home Oxygen Therapy Delivers Strong Real-World Wound Healing Results

AOTI, Inc. ( (GB:AOTI) ) has shared an announcement.

AOTI, Inc., a medical technology group specializing in non-invasive therapies for severe and chronic wounds, focuses on its proprietary Topical Wound Oxygen (TWO2) system, which patients can use at home to treat lower extremity ulcers. With extensive regulatory clearances and favorable health-technology assessments in key markets, the company targets improved clinical outcomes and lower costs in chronic wound care.

The company reported results from a large multicentre real-world cohort of 3,126 patients with chronic lower extremity wounds showing a 64.8% complete healing rate using intermittent TWO2 therapy alongside standard care, despite an average pre-treatment wound age of seven months. Recurrence requiring retreatment was just 2.7%, while hospitalizations and amputations occurred in 3.7% and 6.1% of patients respectively, figures that AOTI says compare favorably with historical norms and support broader adoption of TWO2 as a clinically effective and potentially cost-saving option for high-risk patients and health systems.

Spark’s Take on AOTI Stock

According to Spark, TipRanks’ AI Analyst, AOTI is a Neutral.

The score is primarily constrained by ongoing losses and weak cash flow sustainability despite strong revenue growth and improved margins. Technicals are supportive but show signs of being stretched, and valuation is pressured by negative earnings with no dividend support.

To see Spark’s full report on AOTI stock, click here.

More about AOTI, Inc.

AOTI, Inc. is a medical technology group founded in 2006 and based in Oceanside, California, and Galway, Ireland, that develops non-invasive therapies to treat severe and chronic wounds worldwide. Its flagship product is the patented Topical Wound Oxygen (TWO2) therapy, an at-home treatment for lower extremity wounds such as diabetic foot and venous leg ulcers, which has regulatory clearance across major global markets and positive reimbursement guidance in Germany and the U.K.

TWO2 therapy has been supported by robust randomized controlled trials and real-world evidence showing durable reductions in wound recurrence, hospitalizations, and amputations. By enabling patients to self-administer care at home, AOTI aims to reduce healthcare costs, improve access and adherence, and strengthen its position in the chronic wound management market.

Average Trading Volume: 29,075

Technical Sentiment Signal: Hold

Current Market Cap: £45.2M

See more data about AOTI stock on TipRanks’ Stock Analysis page.